Widespread use of nirsevimab in infants may reduce RSV-related hospitalisations by more than half, suggests a real-world study published in the Medical Journal of Australia.

WA’s State Government was the first to offer funded, statewide RSV immunisation with nirsevimab (Beyfortus) back in April 2024.

From April 2024 to September 2024, all infants entering their first RSV season (born in or after October 2023), as well as children aged 8-19 months at increased risk of severe RSV, were eligible to receive nirsevimab.

Around 21,900 of 30,900 (71%) eligible infants received the injection.